An Open Label, Multi-Center, Non-Interventional Post-Marketing Surveillance to Monitor the Safety and Efficacy of ALTARGO® (Retapamulin) Administered in Korean Patients According to the Prescribing Information.
- Author:
Woosung HONG
1
;
Yil Seob LEE
;
Chun Wook PARK
;
Moon Soo YOON
;
Young Suck RO
Author Information
- Publication Type:Multicenter Study ; Original Article
- Keywords: Anti-bacterial agents; Product surveillance; postmarketing; Skin diseases; infection
- MeSH: Anti-Bacterial Agents; Drug-Related Side Effects and Adverse Reactions; Health Services Needs and Demand; Humans; Incidence; Observational Study; Prospective Studies; Skin; Skin Diseases
- From:Annals of Dermatology 2018;30(4):441-450
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: With the approval of topical retapamulin ointment in 2011, it was officially required to conduct a post-marketing surveillance (PMS) study to obtain further data of its safety profile and effectiveness, in accordance with the requirement of the Korean Ministry of Food and Drug Safety (MFDS). OBJECTIVE: This study had prospectively designed to monitor safety and tolerability with the effectiveness of topical retapamulin in clinical practices. METHODS: Open label, multi-center, non-interventional observational study was done from May 2011 to October 2015. All subjects had bacterial skin infections of locally approved prescribing information accordingly. The study mainly focused on safety issues in the local target population (3,612 eligible subjects). And, drug effectiveness was also evaluated by physicians. RESULTS: The incidence of adverse events (AEs) and adverse drug reactions (ADRs) were 2.53% and 0.97%, respectively. In terms of the incidence of unexpected AEs and ADRs, 1.45% and 0.33%, and for the incidence of serious AEs, 0.28%, whereas no serious ADRs reported. And, the effectiveness of topical retapamulin rate was 96.1% (1,697 of total 1,765 subjects). CONCLUSION: Topical retapamulin is to be well-tolerated and effective in patients with bacterial skin infections of locally approved prescribing information.
